| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Everolimus |
| Brand | Votubia® |
| Indication | For the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery |
| Assessment Process | |
| Rapid review commissioned | 30/09/2011 |
| Rapid review completed | 14/10/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.